Andrew Brenner - Concepedia

Author

Andrew Brenner

The University of Texas Health Science Center at San Antonio ORCID

Also Known As

A Brenner, A J Brenner, A. Brenner, A. J. BRENNER, A. J. Brenner, A.J. Brenner, Andrew Brenner, Andrew J Brenner, Andrew J. Brenner, Andrew Jacob Brenner

518

Publications

8.8K

Citations

H-Index

175

Concepts

All Affiliations

The University of Texas Health Science Center at San Antonio The University of Texas MD Anderson Cancer Center The University of Texas at Austin Mays Cancer Center at UT Health San Antonio The University of Texas at San Antonio

About

Andrew Brenner is an author at The University of Texas Health Science Center at San Antonio specializing in medicine, engineering, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	38	2.4K
2	Engineering	17	21	865
3	Health Sciences	8	8	224
4	Natural Sciences	4	4	176
5	Education	1	1	17

Andrew Brenner

112

Publications

7.7K

Citations

H-Index

Page 1

	Year	Citations
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors Muhammad S. Beg, Andrew Brenner, Jasgit C. Sachdev, Investigational New Drugs Tumor BiologyMedicinePathologyAdvanced Solid TumorsExtracellular Microvesicles	2016	855
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours David S. Hong, Yoon‐Koo Kang, Mitesh J. Borad, British Journal of Cancer	2020	850
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma Linda M. Liau, Keyoumars Ashkan, David D. Tran, Journal of Translational Medicine	2018	528
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma Linda M. Liau, Keyoumars Ashkan, Steven Brem, JAMA Oncology	2022	356
Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation Andrew Brenner, Martha R. Stampfer, C. Marcelo Aldaz Oncogene Cancer ResearchDevelopmental BiologyFirst Senescence ArrestCell RegulationHuman Growth	1998	268
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau, EClinicalMedicine	2021	250
ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases Priya Kumthekar, Shou‐Ching Tang, Andrew Brenner, Clinical Cancer Research	2020	230
A Quantitative Test for Copper Using Bicinchoninic Acid Andrew Brenner, Edward D. Harris Analytical Biochemistry Quantitative TestTrace MetalAnalytical ChemistryMetal ToxicityChemistry	1995	194
Phase I Study of GRN1005 in Recurrent Malignant Glioma Jan Drappatz, Andrew Brenner, Eric T. Wong, Clinical Cancer Research	2013	177
Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors Razelle Kurzrock, N. Gabrail, Chandtip Chandhasin, Molecular Cancer Therapeutics Neuro-oncologyOncologyBrain MetastasesMedicineNovel Conjugate	2011	168

Page 1